Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric pulses may boost a drug's power against painful vascular malformations

NCT ID NCT07720570

Symptom relief Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

Slow-flow vascular malformations — abnormal clusters of veins, capillaries, or lymph vessels — can cause pain, swelling, and appearance concerns. This study follows 60 children and adults who receive bleomycin electrosclerotherapy (BEST), a procedure that injects the drug bleomycin into the malformation and then applies brief electrical pulses to increase its local effect. Researchers track symptom changes and quality of life over six months using patient questionnaires and MRI scans, aiming to see whether BEST offers meaningful relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bleomycin electrosclerotherapy (BEST) — a procedure that injects bleomycin into the malformation and applies brief electrical pulses to boost its effect
What this could lead to
If it works, BEST could become a standard, less invasive option to ease pain, swelling, and appearance concerns from slow-flow vascular malformations.
What could go wrong
This is a small observational study with no control group, so improvements may not be due to the treatment. Side effects from bleomycin or the electrical pulses are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Potential participants are identified among children and adults with slow-flow vascular malformations assessed by the multidisciplinary vascular malformation team at Copenhagen University Hospital - Rigshospitalet.

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Scheduled to undergo BEST as part of routine clinical care * Diagnosis of a slow-flow vascular malformation confirmed by contrast-enhanced MRI performed within 6 months before enrollment. Exclusion Criteria: • Invasive treatment of the vascular malformation within 6 months before enrollment, including surgery, sclerotherapy, or laser treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vascular malformations are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vascular malformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vascular malformations

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Copenhagen University Hospital - Rigshospitalet

    Copenhagen, Capital Region of Denmark, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.